Huntington's Disease, Investor AnnouncementMay 14, 2014
Prana Biotechnology (ASX:PBT, NASDAQ: PRAN) is pleased to invite investors to watch a video interview of Professor Ira Shoulson, following his appointment to the Board of Directors of Prana Biotechnology In the interview, Professor Shoulson comments on:
  • Rationale for joining the Board of Directors and his background;
  • Significance of the recent REACH2HD trial of PBT2 in Huntington disease (HD) patients;
  • The state of therapeutics for patients with HD;
  • Recent IMAGINE trial of PBT2 in Alzheimer's disease (HD) patients; and
  • An overview of Prana's library of compounds.
The video interview is available via the following link: Interview with Professor Ira Shoulson

You can access access other PBT webcasts at BRR media.
distributed by